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Abstract
The use of pulmonary artery catheters is under debate yet again.
We look at two recent trials evaluating their impact on mortality.
Our suspicions regarding obesity are proven and we also look at a
simple, cost effective method of reducing ventilator-associated
pneumonia. Finally, an intervention to improve the poor outcome
associated with out-of hospital cardiac arrests is evaluated.
A dying Swan: FACTT or fiction?
The invention of the pulmonary artery catheter (PAC) 38
years ago by Drs Jeremy Swan and William Ganz was
embraced by the medical world wholly and enthusiastically. It
was presumed that the increased information provided would
help deliver a more tailored and scientific approach to our
critically unwell patients. However, concerns regarding their
usefulness and safety are increasingly evident [1], and, with
the development of alternative tools to calculate haemo-
dynamic parameters, the use of the PAC is dwindling.
The latest study to question their use compares PAC to
central venous catheter (CVC) guided therapy in the
management of 1,000 patients with newly established acute
lung injury in a multi-centre prospective randomised trial [2].
This ‘Fluid and Catheter Treatment Trial’ (FACTT) assessed
60 day mortality, fluid balance, ventilator-free days, intensive
therapy unit (ITU) length of stay and complication rates.
Catheter-derived haemodynamic parameters and clinical
measures were used in conjunction with explicit protocols to
guide fluid, inotrope and diuretic management.
Mortality rates were similar in both groups (27.4% PAC and
26.3% CVC), as were the number of ventilator-free days
during the first 28 days (mean, 13.2 and 13.5, respectively).
Fluid balance was similar in both groups, as was the
incidence and duration of any type of organ failure. ITU stay
was reduced in the CVC group, although the authors do
acknowledge the mere presence of a PAC in a patient may
have prevented discharge from ITU to a ward, thus causing
erroneous results.
Complication rates for both groups were similar per catheter
insertion. However, PAC patients, in whom a CVC may have
been placed once haemodynamically stable, received 50%
more catheters, thus increasing the total number of
complications, mostly arrhythmias, in this group.
Is the ‘Swan’ destined for extinction? Proponents of PAC will
point out that the conclusion only applies to a relatively young
(median age 50 years), medical ITU population and excluded
the majority of the 11,511 patients screened. These
proponents will favour the study by Friese and colleagues [3],
who scrutinised the American National Trauma Data Bank in
a retrospective database analysis to assess the role of PACs
on mortality in adult trauma patients admitted to ITU over an
eight year period.
The 53,312 patients were initially divided into two groups:
those that received a PAC as part of their management (4%)
and those that did not. Subsequently, they were divided
according to age, Injury Severity Score and initial base deficit.
Unsurprisingly, a higher use of PACs and a greater mortality
rate was noted in patients with high Injury Severity Score,
greater initial base deficits and increasing age. Interestingly,
however, patients in all age groups appeared to benefit from
a PAC if they had an initial base deficit of –11 or worse, with
a high Injury Severity Score (25 to 75). Elderly patients (age
61 to 90 years) with a high Injury Severity Score also seemed
to benefit from a PAC with a moderate base deficit (–6 to
–10). All other groups showed an increased mortality if a
PAC was used.
As conceded by the authors, this paper has several
limitations and the discussion is worthwhile reading. The
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authors conclude that this study is appropriate for the
generation, rather than testing, of new hypotheses.
Obesity: a large predictor of mortality
Obesity is epidemic in the United States of America. In 2004,
the prevalence of adults with a body mass index >30 was
32% [4]. In the latest health survey in the UK, 23.7% of our
adult population has a body mass index >30 [5]. A figure that
continues to rise at an alarming rate.
Nasraway and colleagues [6] have now shown morbid
obesity (body mass index >40 kg/m2) to be an independent
predictor of mortality in surgical patients in intensive care
units [6]. Prospective data over a three year period was
analysed and corrected for age, gender and illness severity.
The odds of death increased 7.4 times in morbidly obese
patients requiring intensive care for 4 days or more.
Physiological changes, co-morbidities, practical difficulties
and altered pharmacokinetics associated with obesity are just
a few of the challenging issues unique to this subset of
patients. As obesity prevalence continues to rise, hospitals
and health care providers will need to devote more thought
and resources to help tackle this escalating problem.
Wash your mouth out
Alternative methods for reducing the incidence of ventilator
acquired pneumonia (VAP) have received some attention of
late. VAP has previously been shown to significantly increase
both morbidity and mortality.
Two recent trials [7,8] have shown a reduction in VAP rates
by using antiseptics for oropharyngeal decontamination in
intubated patients. Previous trials, using both intravenous and
topical non-absorbable antibiotics in VAP prophylaxis, have
shown good results, but concerns regarding development of
bacterial resistance, side effects and cost implications remain
[9-11].
The French study, by Seguin and colleagues [7], con-
centrated on reducing VAP in intubated, closed head injury
patients in whom ventilation was necessary for ≥48 hours,
using a 10% povidone-iodine solution as an oropharyngeal
cavity rinse 4 hourly. Povidone-iodine solution has both
Gram-positive and negative action, with minimal resistance
phenomena having been reported.
They compared three groups – a placebo group that received
routine suctioning and mouth care, a saline rinse group and
the study group. VAP was diagnosed according to strict
criteria.
A 5-fold reduction in VAP prevalence was demonstrated in
the study group (3 of 36 patients (8%) in the study group, 12
of 31 patients (39%) in the saline group, 13 of 31 patients
(42%) in the control group). Mortality and length of ITU stay
remained unchanged. Only one multiresistant bacteria was
isolated, that being in the control group.
Koeman and colleagues [8] from the Netherlands performed
a similar study across a multicentre, general ITU setting. A
buccal paste containing either chlorhexidine 2% (CHX),
chlorhexidine 2%/colistin 2% (CHX/COL) or placebo was
administered four times daily to intubated patients.
Chlorhexidine has minimal Gram-negative cover, unlike
colistin, but is effective against Gram-positive bacteria, inclu-
ding methicillin-resistant Staphylococcus aureus (MRSA).
Colistin has both Gram-positive and negative cover, but is
generally reserved for treatment of multiresistant Gram-
negatives. Criteria for diagnosing VAP were similar to those in
the French study.
Oropharyngeal decontamination with either CHX or CHX/
COL reduced and delayed the development of VAP. Daily risk
of acquiring VAP decreased: 65% and 55% for CHX and
CHX/COL, compared with the placebo group, respectively.
Again, mortality and length of ITU were not affected.
Both studies offer a simple, safe and cost effective approach
to tackling VAP. Future studies should be blinded and
powered for mortality and length of stay.
Aminophylline
Another attempt to improve outcome in out-of-hospital
cardiac arrest patients has, unfortunately, not returned any
improvement in survival rate [12]. Attention was drawn to the
use of aminophylline in an attempt to inhibit the effects of
adenosine on electrical activity in the heart. Adenosine, an
endogenous purine released during myocardial ischaemia,
depresses the sino-atrial node, atrioventricular conduction,
pacemaker activity of the His-Purkinje system and catechol-
amine action. Aminophylline was used following routine
administration of adrenaline and atropine in an unresponsive
patient who presented with either asystole or bradycardic
pulseless electrical activity. Median time to drug adminis-
tration was therefore prolonged (13 minutes). A further
10 minutes of CPR continued following its administration in
this double-blind, randomised prospective study.
Sadly, no improvement in return of spontaneous circulation,
survival to hospital admission or hospital discharge could be
shown.
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